Cosmos Health Expands Order Book with Contract Manufacturing Agreement with Medical Pharmaquality S.A. for 3 Million MYCOFAGYL® Pessaries Annually
Cosmos Health (NASDAQ:COSM) has announced that its subsidiary Cana Laboratories has secured a contract manufacturing agreement with Medical Pharmaquality S.A. for the production of MYCOFAGYL® pessaries. The agreement entails manufacturing 3 million pessaries annually, packaged in 10-unit sets.
MYCOFAGYL® combines Metronidazole (500mg) and Nystatin (100,000 IU) to treat vaginal infections, including bacterial vaginosis and candidiasis. This expansion into gynecological products represents a strategic diversification of Cana's manufacturing portfolio and strengthens its position in the European pharmaceutical market.
Cosmos Health (NASDAQ:COSM) ha annunciato che la sua controllata Cana Laboratories ha ottenuto un accordo di fabbricazione in conto terzi con Medical Pharmaquality S.A. per la produzione di MYCOFAGYL® pessari. L'accordo prevede la realizzazione di 3 milioni di pessari all'anno, confezionati in lotti da 10 unità.
MYCOFAGYL® combina Metronidazolo (500 mg) e Nistatina (100.000 UI) per trattare infezioni vaginali, tra cui vaginosi batterica e candidosi. Questa espansione nel settore ginecologico rappresenta una diversificazione strategica del portafoglio di produzione di Cana e rafforza la sua posizione nel mercato farmaceutico europeo.
Cosmos Health (NASDAQ:COSM) anunció que su filial Cana Laboratories ha cerrado un acuerdo de fabricación por contrato con Medical Pharmaquality S.A. para la producción de MYCOFAGYL® pessarios. El acuerdo contempla fabricar 3 millones de pessarios al año, en envases de 10 unidades.
MYCOFAGYL® combina Metronidazol (500 mg) y Nistatina (100,000 UI) para tratar infecciones vaginales, incluida la vaginosis bacteriana y la candidiasis. Esta expansión hacia productos ginecológicos representa una diversificación estratégica de la cartera de fabricación de Cana y fortalece su posición en el mercado farmacéutico europeo.
Cosmos Health (NASDAQ:COSM)는 자회사 Cana Laboratories가 Medical Pharmaquality S.A.와 MYCOFAGYL® 질정의 생산을 위한 계약 제조 계약을 체결했다고 발표했습니다. 계약은 연간 300만 개의 질정을 10개 단위로 포장하여 생산하는 것을 포함합니다.
MYCOFAGYL®은 메트로니다졸(500 mg)과 니스타틴(100,000 IU)을 결합해 질염을 포함한 질 감염을 치료합니다. 이 자궁경부/생식기 의약품으로의 확장은 Cana의 제조 포트폴리오를 다각화하고 유럽 제약 시장에서의 위치를 강화합니다.
Cosmos Health (NASDAQ:COSM) a annoncé que sa filiale Cana Laboratories a obtenu un accord de fabrication sous contrat avec Medical Pharmaquality S.A. pour la production de MYCOFAGYL® pessaires. L'accord prévoit la fabrication de 3 millions de pessares par an, conditionnés par lots de 10 unités.
MYCOFAGYL® associe le métronidazole (500 mg) et la nystatine (100 000 UI) pour traiter les infections vaginales, notamment la vaginose bactérienne et la candidose. Cette expansion vers les produits gynécologiques représente une diversification stratégique du portefeuille de fabrication de Cana et renforce sa position sur le marché pharmaceutique européen.
Cosmos Health (NASDAQ:COSM) hat angekündigt, dass seine Tochtergesellschaft Cana Laboratories eine Auftragsfertigung mit Medical Pharmaquality S.A. für die Produktion von MYCOFAGYL® Vaginaltabletten abgeschlossen hat. Der Vertrag sieht die Herstellung von 3 Millionen Vaginaltabletten pro Jahr vor, verpackt in 10-Einheiten-Sets.
MYCOFAGYL® kombiniert Metronidazol (500 mg) und Nystatin (100.000 UI) zur Behandlung vaginaler Infektionen, einschließlich bakterieller Vaginosis und Candidiasis. Diese Expansion in gynäkologische Produkte stellt eine strategische Diversifizierung des Produktionsportfolios von Cana dar und stärkt seine Position im europäischen Pharmamarkt.
Cosmos Health (NASDAQ:COSM) أعلن أن شركة Cana Laboratories التابعة لها قد أبرمت اتفاق تصنيع بعقد مع Medical Pharmaquality S.A. لإنتاج تحاميل مهبلية MYCOFAGYL®. ينص الاتفاق على تصنيع 3 ملايين تحاميل في السنة، مع تعبئتها في مجموعات من 10 وحدات.
يجمع MYCOFAGYL® بين الميترونيدازول (500 mg) والنّيستاتين (100,000 UI) لعلاج الإصابات المهبلية، بما في ذلك التهاب المهبل الناتج عن عدوى بكتيرية والعدوى الفطرية. يمثل هذا التوسع في المنتجات النسائية توسعاً استراتيجياً لمحفظة Cana التصنيعية ويقوّي موقعها في السوق الدوائي الأوروبي.
Cosmos Health (NASDAQ:COSM) 宣布其子公司 Cana Laboratories 已与 Medical Pharmaquality S.A. 签署代工协议，生产 MYCOFAGYL® 阴道栓。该协议规定年产 300万枚阴道栓，以10单位一组进行包装。
MYCOFAGYL® 将甲硝唑 (500 mg) 与尼司他丁（100,000 IU）结合，用于治疗阴道感染，包括细菌性阴道病和念珠菌性阴道炎。这一向妇科产品领域的扩张代表了 Cana 制造组合的战略多样化，并加强其在欧洲制药市场的地位。
- Secured long-term manufacturing contract for 3 million MYCOFAGYL® pessaries annually
- Expansion into gynecology market segment diversifies product portfolio
- Agreement expected to generate high-margin revenue and strengthen cash flow
- Reinforces Cana's position as a trusted pharmaceutical manufacturing partner in Europe
- None.
Insights
Cosmos Health's new contract to manufacture 3M MYCOFAGYL pessaries annually strengthens revenue stream and expands into women's healthcare market.
Cosmos Health's subsidiary Cana Laboratories has secured a substantial manufacturing contract with Medical Pharmaquality S.A. that adds 3 million MYCOFAGYL pessaries annually to their production pipeline. This deal strategically diversifies their product portfolio into the gynecological therapeutics market while leveraging their existing manufacturing infrastructure.
The MYCOFAGYL product contains a dual-action combination of Metronidazole (500mg) and Nystatin (100,000 IU) for treating common vaginal infections. This represents a differentiated offering in the women's health space, where combination therapies that address multiple infection types simultaneously can be particularly valuable for patient compliance and treatment outcomes.
From a business perspective, this agreement is particularly significant as it establishes a long-term, high-volume commitment that should provide predictable manufacturing revenue. Contract manufacturing agreements typically offer more stable cash flow compared to direct consumer products that might face seasonal fluctuations or competitive pressures.
The company's strategic expansion into women's health broadens Cana's therapeutic reach, potentially opening doors to additional contract manufacturing opportunities in adjacent gynecological product categories. By highlighting Cana's manufacturing capabilities through this high-volume production agreement, Cosmos demonstrates its ability to secure partnerships that utilize its production capacity while generating consistent revenue.
CHICAGO, Sept. 25, 2025 (GLOBE NEWSWIRE) -- Cosmos Health Inc. (“Cosmos Health” or the “Company”) (NASDAQ:COSM), a diversified, vertically integrated global healthcare group, today announced that its wholly owned subsidiary, Cana Laboratories S.A. (“Cana”), has signed a contract manufacturing agreement with Medical Pharmaquality S.A. for MYCOFAGYL® pessaries, further expanding its pipeline of pharmaceutical products.
Under the terms of the agreement, Cana will manufacture MYCOFAGYL®, a combination of Metronidazole (500mg) and Nystatin (100,000 IU) in pessary dosage form. The product will be supplied in packs of 10 units (2 PVC/PE strips x 5 pessaries). The Company anticipates manufacturing and delivering 3 million pessaries per year.
MYCOFAGYL® is widely prescribed for the treatment of vaginal infections, including bacterial vaginosis and candidiasis (yeast infections). By combining the antibacterial and antiprotozoal action of Metronidazole with the antifungal action of Nystatin, MYCOFAGYL® provides a dual-action approach that helps restore balance and effectively treat common vaginal infections such as bacterial vaginosis and candidiasis.
This agreement highlights Cana’s expertise in high-quality pharmaceutical manufacturing and expands its portfolio to include gynecology, adding to the wide range of therapeutic categories in which the company is active. By broadening its scope, Cana reinforces its position as a trusted partner to pharmaceutical companies across Europe and beyond.
Greg Siokas, CEO of Cosmos Health, stated: “We are excited to expand our order book with long-term, high-volume commitments, further reinforcing Cana’s reputation as a reliable partner in the pharmaceutical industry. This agreement reflects our partner’s confidence in Cana’s quality, expertise, and state-of-the-art facilities, while MYCOFAGYL represents another step in our strategy to diversify our product offerings. Women’s health remains a critical therapeutic area, and this agreement not only strengthens our manufacturing pipeline but also underscores the strong growth momentum of our contract manufacturing business and our ability to secure new high-margin contracts that strengthen our cash flow.”
About Medical Pharmaquality S.A.
Medical Pharmaquality S.A., headquartered in Athens, Greece, is a diversified healthcare company engaged in the manufacture, distribution, and development of medicinal products for human use. Its portfolio spans a broad range of therapeutic areas, including infectious diseases, gastrointestinal health, metabolic disorders, cardiovascular disease, osteoporosis, neuropsychiatric conditions, respiratory health, joint health, and men’s health, while also covering pharmacy-level wellness products and cosmetics through its affiliated brand M Cosmetics. With a focus on scientific rigor, quality, and regulatory compliance, Medical Pharmaquality S.A. provides partners with a robust platform for product development and distribution.
About Cosmos Health Inc.
Cosmos Health Inc. (Nasdaq:COSM), incorporated in 2009 in Nevada, is a diversified, vertically integrated global healthcare group. The Company owns a portfolio of proprietary pharmaceutical and nutraceutical brands, including Sky Premium Life®, Mediterranation®, bio-bebe®, C-Sept® and C-Scrub®. Through its subsidiary Cana Laboratories S.A., licensed under European Good Manufacturing Practices (GMP) and certified by the European Medicines Agency (EMA), it manufactures pharmaceuticals, food supplements, cosmetics, biocides, and medical devices within the European Union. Cosmos Health also distributes a broad line of pharmaceuticals and parapharmaceuticals, including branded generics and OTC medications, to retail pharmacies and wholesale distributors through its subsidiaries in Greece and the UK. Furthermore, the Company has established R&D partnerships targeting major health disorders such as obesity, diabetes, and cancer, enhanced by artificial intelligence drug repurposing technologies, and focuses on the R&D of novel patented nutraceuticals, specialized root extracts, proprietary complex generics, and innovative OTC products. Cosmos Health has also entered the telehealth space through the acquisition of ZipDoctor, Inc., based in Texas, USA. With a global distribution platform, the Company is currently expanding throughout Europe, Asia, and North America, and has offices and distribution centers in Thessaloniki and Athens, Greece, and in Harlow, UK. More information is available at www.cosmoshealthinc.com, www.skypremiumlife.com, www.cana.gr, www.zipdoctor.co, www.cloudscreen.gr, as well as LinkedIn and X.
Forward-Looking Statements
With the exception of the historical information contained in this news release, the matters described herein, may contain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Statements preceded by, followed by, or that otherwise, include the words "believes," "expects," "anticipates," "intends," "projects," "estimates," "plans" and similar expressions or future or conditional verbs such as "will," "should," "would," "may" and "could", are generally forward-looking in nature and not historical facts, although not all forward-looking statements include the foregoing. Such forward-looking statements include, but are not limited to, the Company’s expectation that accumulation of ETH will enhance long-term shareholder value through increasing ETH-per-share, the Company’s plans to explore additional yield-generating strategies to optimize cash flow and utility from ETH holdings, that our facility with ATW Digital Asset Opportunities VII LLC will provide access to growth capital to support a range of strategic initiatives, including accelerated product development, advanced R&D innovation, enhanced commercial initiatives, and the Company’s planned entry into U.S. manufacturing and the anticipated use of proceeds. These statements, involve unknown risks and uncertainties that may individually or materially impact the matters discussed, herein for a variety of reasons that are outside the control of the Company, including, but not limited to, the Company's ability to raise sufficient financing to implement its business plan, and the Company's ability to successfully develop and commercialize its proprietary products and technologies. Readers are cautioned not to place undue reliance on these forward- looking statements, as actual results could differ materially from those described in the forward-looking statements contained herein. Readers are urged to read the risk factors set forth in the Company's filings with the SEC, which are available at the SEC's website (www.sec.gov). The Company disclaims any intention or obligation to update, or revise any forward-looking statements, whether as a result of new information, future events or otherwise.
Investor Relations Contact:
BDG Communications
cosm@bdgcommunications.com
FAQ
What is the new manufacturing agreement between Cosmos Health and Medical Pharmaquality?
What is MYCOFAGYL® and what does it treat?
How will this agreement impact Cosmos Health's (NASDAQ:COSM) business?
What are the packaging specifications for MYCOFAGYL® under this agreement?
